Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 5/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.49 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.49 |
| ▸ | ITGB2 | P05107 | 3/20 | 0.42 |
| ▸ | ICAM1 | P05362 | 3/20 | 0.42 |
| ▸ | ITGAL | P20701 | 3/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 6/20 | 0.42 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | SMO | Q99835 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21434028 | 0.91 | CHRM2 (0.47) | CHRM2CHRM1CHRM3ITGB2ICAM1 | |
| SCHEMBL21434030 | 0.90 | KMO (0.50) | CHRM2CHRM1CHRM3ITGB2ICAM1 | |
| SCHEMBL21433966 | 0.88 | CHRM2 (0.49) | CHRM2CHRM1CHRM3CHRM4CD274 | |
| SCHEMBL21433969 | 0.87 | CHRM4 (0.51) | CHRM2CHRM1CHRM4EPHX2 | |
| SCHEMBL21434163 | 0.86 | ITGB2 (0.55) | CHRM2CHRM1CHRM3ITGB2ICAM1 | |
| SCHEMBL21434106 | 0.81 | ITGB2 (0.50) | ITGB2ICAM1ITGALEPHX2SMO | |
| SCHEMBL21434009 | 0.81 | CHRM2 (0.46) | CHRM2CHRM1CHRM3CHRM4KDM4E | |
| SCHEMBL21452927 | 0.81 | ITGB2 (0.47) | ITGB2ICAM1ITGALCHRM4EPHX2 | |
| SCHEMBL21452903 | 0.80 | KMO (0.48) | CHRM1CHRM3ITGB2ICAM1ITGAL | |
| SCHEMBL21452765 | 0.79 | ITGB2 (0.40) | ITGB2ICAM1ITGALKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210340121-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-11-04 | — | — | US | claimed |
| EP-3774732-A2 | SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | Janssen Pharmaceutica NV (BE) | 2021-02-17 | — | — | EP | claimed |
| WO-2019193516-A2 | SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-10-10 | — | — | WO | claimed |
| US-20190308950-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-10-10 | — | — | US | claimed |
| US-20210340121-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-11-04 | — | — | US | disclosed |
| US-20210340121-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-11-04 | — | — | US | disclosed |
| US-11008302-B2 | Substituted pyridine and pyrimidines and their use as GluN2B receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2021-05-18 | — | — | US | disclosed |
| US-11008302-B2 | Substituted pyridine and pyrimidines and their use as GluN2B receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2021-05-18 | — | — | US | disclosed |
| EP-3774732-A2 | SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | Janssen Pharmaceutica NV (BE) | 2021-02-17 | — | — | EP | disclosed |
| WO-2019193516-A2 | SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-10-10 | — | — | WO | disclosed |
| WO-2019193516-A2 | SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-10-10 | — | — | WO | disclosed |
| US-20190308950-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-10-10 | — | — | US | disclosed |
| US-20190308950-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190308950-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN3B | CHRM2 699/4885CHRM1 781/4885CHRM3 648/4885 |
| US-20210340121-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN3B | CHRM2 699/4885CHRM1 781/4885CHRM3 648/4885 |
| US-11008302-B2 | Substituted pyridine and pyrimidines and their use as GluN2B receptor modulators | GRIN2B, GRIN2A, GRIN3B | CHRM2 720/4885CHRM1 750/4885CHRM3 651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.